Advertisement
Advertisement
U.S. markets closed
Advertisement
Advertisement
Advertisement
Advertisement

InflaRx N.V. (IFRX)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
4.2500+0.1600 (+3.91%)
At close: 04:00PM EST
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Double Moving Average Crossover

Double Moving Average Crossover

Previous Close4.0900
Open3.9400
Bid4.2200 x 800
Ask4.3100 x 1400
Day's Range3.9400 - 4.2900
52 Week Range2.2300 - 6.3800
Volume184,334
Avg. Volume3,020,290
Market Cap187.792M
Beta (5Y Monthly)0.68
PE Ratio (TTM)N/A
EPS (TTM)-1.2690
Earnings DateMar 23, 2022 - Mar 28, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est9.63
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for IFRX

Learn more
View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • InflaRx N.V.
    Morningstar | A Weekly Summary of Stock Ideas and Developments in the Companies We CoverThis edition features our annual pharmaceutical pipeline, a fresh look at Barry Callebaut's chocolate operation, the buzz around RingCentral, and SAP, Subsea 7, and Just Eat Takeaway.
    Rating
    Fair Value
    Economic Moat
    3 days agoMorningstar
View more
  • GlobeNewswire

    InflaRx Announces New Pipeline Program – Oral C5aR Inhibitor

    Regulatory discussions on Phase I program have been initiatedFirst-in-human study expected to start in the second half of 2022 JENA, Germany, Jan. 10, 2022 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a clinical-stage biopharmaceutical company developing anti-inflammatory therapeutics by targeting the complement system, today announced a new pipeline program, INF904, an oral small molecule inhibitor of C5aR. “Inhibition of the C5a/C5aR axis provides strong anti-inflammatory effects in a vari

  • GlobeNewswire

    InflaRx Announces Presentation at J.P. Morgan Healthcare Conference and Other Investor Events

    Presentation at J.P. Morgan Healthcare Conference on January 13thCorporate presentation for H.C. Wainwright BioConnect Conference available online starting January 10thCompany to host virtual R&D Event on vilobelimab in Hidradenitis Suppurativa on February 3rd JENA, Germany, Jan. 05, 2022 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a clinical-stage biopharmaceutical company developing anti-inflammatory therapeutics by targeting the complement system, today announced its participation at sev

  • Benzinga

    InflaRx's Vilobelimab Shows Encouraging Action Against Rare Autoimmune Disorder

    InflaRx N.V. (NASDAQ: IFRX) has announced data from the European Phase II IXCHANGE study of vilobelimab in patients with ANCA-associated vasculitis (AAV). The trial demonstrated a comparable clinical response of vilobelimab to the standard of care, significantly reducing the need for glucocorticoid (GC) treatment. Clinical response at week 16 in evaluable patients was observed in 16 out of 18 patients in the treatment group receiving vilobelimab alone; in 22 out of 23 patients receiving a standa

Advertisement
Advertisement